TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean costs of diagnostic and therapeutic procedures per hospital inpatient day
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: BMI gains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weight for age Z-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shoulder function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change in LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: improved self-esteem
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: decreased social embarrassment
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: lower impact on normal daily activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: lowest SpO2 during the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: required fewer dose adjustments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative propofol dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal oxidative work capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of complications
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with IOP of 21 mm Hg or lower without ocular hypotensive medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Forced expiratory flow improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: improvement in neuropsychological domains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to full enteral feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Superior mesentery artery peak velocity (Vmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Weight gain after 14 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: voice evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke Volume Variation (SVV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of Rocuronium Effect (TR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: MCP-1 concentration change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delta LV end-systolic volume index (DeltaLVESVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Delta LV ejection fraction (DeltaLVEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mucositis scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in mHHS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative dezocine dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequencies of severe vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Frequencies of hypotension
Endpoint domain: Adverse events/effects
Primary endpoint: Proportions with HIV‐1 RNA <50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions with HIV‐1 RNA <200 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent surface microhardness recovery (% SMHr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent relative erosion resistance (% RER)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gastrointestinal function recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in scores on the Pathological Laughter and Crying Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: rate of repetitions of exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-month minimal disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: incidence of sICH
Endpoint domain: Adverse events/effects
Primary endpoint: postoperative vaginal blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nursing verbal pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ketorolac use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Teamwork performance (CTS score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of predefined obstetric procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QTd and QTcd changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Leg pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oswestry disability score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms bothersomeness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: BMG removal rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percentage of weeks with Hb 10.0 to 11.9 g/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevalence of malaria
Endpoint domain: Adverse events/effects
Primary endpoint: Malaria episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Time to first malaria episode
Endpoint domain: Adverse events/effects
Primary endpoint: Clitoral circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Sexuality score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: microbiological cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to accomplish topical anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: willingness to return and recommend the facility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain relief of >or= 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional improvement of >or= 40%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disruption of chemotherapy
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: baseline visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: baseline visual field defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acid contact time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: haemodynamic performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of hypotensive events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in hazardous tobacco use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in hazardous alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall fat gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: blood lipids (cholesterol, LDL-C, triglycerides)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in productivity loss across the work shift
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Shorter return to normal work performance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Headache relief 1 hour after injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10 year cumulative risk of CIN3+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clinical endpoint for treatment (≤4 sites with probing depth ≥5 mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difficulties in emotion regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fear of emotional responses
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perceived control over anxiety
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean relapse rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Expanded Disability Status Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fewer steroid courses required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maintaining abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in morning plasma ACTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cardiac arrest rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiogenic shock rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SMBG reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: vascular complication rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: All-cause mortality or disabling stroke
Endpoint domain: Mortality/survival
Primary endpoint: Time to discontinuation for any cause
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time before relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of AMS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in breathing function (FVC, FEV1.0, FEF25%-75%, PEF, MVV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in atrial fibrillation episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients experiencing upper GI AEs considered drug related or that led to discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: RHAL gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in closure time using the PFA-100
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in template bleeding time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: relapse rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: costs per patient after 3 years
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Diabetes remission after bariatric surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lymphorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Complete resection of polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maintenance of high mucosal elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: cancer-related survival
Endpoint domain: Mortality/survival
Primary endpoint: tumor relapse
Endpoint domain: Mortality/survival
Primary endpoint: Intima/media ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global evaluations by investigators and patients
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in mean pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in mean nausea score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of predicted forced vital capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: absolute forced vital capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ventilation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of Aa levels in deep pockets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction of PD (probing depth)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival recession
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle attenuation of the rectus femoris muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cross-sectional area (CSA) of sartorius, quadriceps and rectus femoris muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hyperphosphatemic episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Quality-adjusted life-year (QALY) gained
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Seizure reduction of more than 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Complete seizure freedom
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Major adverse events necessitating KD withdrawal
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of bat contact with date palm sap
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of IL-10-1082 A/A homozygous genotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of IL-6-174 C/C homozygous genotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of TNF-a-308 A/A homozygous genotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Short-term mortality
Endpoint domain: Mortality/survival
Primary endpoint: fatigue score improvement
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Scar formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pain and pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean progression rates of IMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bone Turnover Markers (BTMs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) for buspirone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean ratio (GMR) for buspirone AUC with GFJ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean ratio (GMR) for flurbiprofen AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Creatine kinase isoenzyme MB at 24 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: subjective health state
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: vital distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: maximum performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative tissue oxygen tension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative P(sq)O(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Capillary blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude of oesophageal body contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Lower oesophageal sphincter pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of complete resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Three-year event-free survival
Endpoint domain: Mortality/survival
Primary endpoint: 24-hour postoperative hemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: frequency of homologous blood product use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: impairment of continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: day the patient returned to work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: positive, negative, depressive, or obsessive-compulsive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-adherence during TB treatment
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: ACQ scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mini-AQLQ scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: non-fatal myocardial infarction, non-fatal stroke, resuscitated cardiac arrest or cardiovascular death
Endpoint domain: Mortality/survival
Primary endpoint: BUT (Breakup Time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluorescein and rose bengal staining scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective symptoms (dry eye sensation, pain, foreign body sensation)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of death or hospitalization for heart failure (HF)
Endpoint domain: Mortality/survival
Primary endpoint: Rate of admission for heart failure (HF)
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline in MVS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of vertigo-associated nausea
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intensity of low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flexibility of spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative low output syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Enzymatic myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean duration of neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean number of hospital days on broad-spectrum antibiotics
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Less worsening of cartilage damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of bone marrow lesions (BMLs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinically acceptable marginal integrity rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No color change rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: haemodynamic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: composite of cardiovascular death or hospitalization for HF
Endpoint domain: Mortality/survival
Primary endpoint: Positivity rates for CTC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positivity rates for CA27.29
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Association between CA27.29 and CTC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death from other malignancies
Endpoint domain: Mortality/survival
Primary endpoint: Death from other causes
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in symptoms and syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of MUCSAC mRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of ETAR mRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of BFV measurements with CBF values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: HbA1c levels reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative haemoglobin drop
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction of CFU in endoscope samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients whose skin cleared during treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes